Foghorn Therapeutics Inc Forecast, price target & analysts
Foghorn Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Foghorn Therapeutics Inc Classifications & Recommendation:
Foghorn Therapeutics Inc Price Target
| Target Price | $11.67 |
| Price | $4.14 |
| Potential |
181.80%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Foghorn Therapeutics Inc 2026 .
The average Foghorn Therapeutics Inc target price is $11.67.
This is
181.80%
register free of charge
$14.00
238.16%
register free of charge
$9.00
117.39%
register free of charge
|
|
| A rating was issued by 7 analysts: 7 Analysts recommend Foghorn Therapeutics Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Foghorn Therapeutics Inc stock has an average upside potential 2026 of
181.80%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 22.60 | 29.94 |
| 33.84% | 32.50% | |
| EBITDA Margin | -429.96% | -306.44% |
| 40.60% | 28.73% | |
| Net Margin | -389.55% | -224.23% |
| 2.06% | 42.44% |
7 Analysts have issued a sales forecast Foghorn Therapeutics Inc 2025 . The average Foghorn Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Foghorn Therapeutics Inc 2025 . The average Foghorn Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Foghorn Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Foghorn Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.58 | -1.21 |
| 32.48% | 23.42% | |
| P/E | negative | |
| EV/Sales | 1.50 |
4 Analysts have issued a Foghorn Therapeutics Inc forecast for earnings per share. The average Foghorn Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Foghorn Therapeutics Inc...
Current Foghorn Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JMP Securities |
Locked
➜
Locked
|
Locked | May 15 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 30 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Apr 30 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Apr 23 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
JMP Securities:
Locked
➜
Locked
|
May 15 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 30 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Apr 30 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Apr 23 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Jan 30 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 17 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
